(Q36379337)

13 August 2017

1 reference

title

Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses (English)

1 reference

13 August 2017

1 reference

1 reference

Zhongyu Zhu

1

1 reference

13 August 2017

Antony S Dimitrov

2

1 reference

13 August 2017

Samitabh Chakraborti

3

1 reference

13 August 2017

Dimana Dimitrova

4

1 reference

13 August 2017

Xiaodong Xiao

5

1 reference

13 August 2017

Christopher C Broder

6

1 reference

13 August 2017

Dimiter S Dimitrov

7

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

Expert Review of Anti-infective Therapy

13 August 2017

published in

1 reference

13 August 2017

volume

4

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

57-66

1 reference

Virus entry: molecular mechanisms and biomedical applications

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Passive antibody therapy for infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Passive antibody therapies: progress and continuing challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Serum therapy revisited: animal models of infection and development of passive antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Preventing infectious disease with passive immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Antibodies for the prevention and treatment of viral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Antiviral immunotherapy: a review of current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Successful Intravenous Immunoglobulin Therapy in 3 Cases of Parvovirus B19–Associated Chronic Fatigue Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Treatment of human enterovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

The use of intravenous immunoglobulins in symptomatic HIV infection. Results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

In vivo selection of respiratory syncytial viruses resistant to palivizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

A novel coronavirus associated with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Coronavirus as a possible cause of severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

SARS-Associated Coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Antibody responses against SARS-coronavirus and its nucleocaspid in SARS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

SARS corona virus peptides recognized by antibodies in the sera of convalescent cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

The SARS-CoV S glycoprotein: expression and functional characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

21 January 2018

SARS vaccine development

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Antibodies, viruses and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

A human SARS-CoV neutralizing antibody against epitope on S2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Bats are natural reservoirs of SARS-like coronaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Risk factors for Nipah virus infection among abattoir workers in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Clinical features of Nipah virus encephalitis among pig farmers in Malaysia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Nipah virus: a recently emergent deadly paramyxovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Antibody-dependent enhancement of Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Epitopes involved in antibody-mediated protection from Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Recombinant human monoclonal antibodies to Ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

The pathogenesis of Ebola hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Complement activation is required for induction of a protective antibody response against West Nile virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Structural basis of West Nile virus neutralization by a therapeutic antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Characterization of neutralizing antibodies to West Nile virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Genetic detection and isolation of crimean-congo hemorrhagic fever virus, Kosovo, Yugoslavia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Generation of an HFRS patient-derived neutralizing recombinant antibody to Hantaan virus G1 protein and definition of the neutralizing domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

In the eye of the beholder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.57

21 January 2018

Identifiers

DOI

10.1586/14787210.4.1.57

1 reference

13 August 2017

1 reference